Analysis of clinical data and patient material provides evidence for a particular relevance of our findings in aggressive breast cancer types, showing that a ‘common ZEB1/YAP target gene set' is a strong predictor of poor relapse free survival, therapy resistance and increased metastatic risk. This evidence concerns the gene YAP1 and breast carcinoma.